MAPT and amyloidosis: Although the study did not show any significant effect on cognitive and functional tests overall, post hoc analysis revealed that the vaccine slowed down cognitive and functional decline in AD patients having both amyloid and tau pathology and attenuated white matter degeneration (Novak et al. 2021).